Hamel Associates’s Sanofi SNY Stock Holding History

Hamel Associates’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,025	Closed	-$200K	–	87
2017 Q3	$200K	Buy	+4,025	New	+$195K	0.1%	85
2017 Q1	–	Sell	-7,025	Closed	-$284K	–	86
2016 Q4	$284K	Hold	7,025	–	–	0.15%	75
2016 Q3	$268K	Sell	7,025 -550	-7%	-$22.1K	0.14%	77
2016 Q2	$317K	Sell	7,575 -4,450	-37%	-$182K	0.16%	76
2016 Q1	$483K	Sell	12,025 -625	-5%	-$25.1K	0.26%	64
2015 Q4	$539K	Sell	12,650 -1,275	-9%	-$58.7K	0.34%	57
2015 Q3	$661K	Sell	13,925 -1,850	-12%	-$94.2K	0.47%	57
2015 Q2	$781K	Sell	15,775 -1,050	-6%	-$53.2K	0.51%	58
2015 Q1	$831K	Buy	16,825 +6,900	+70%	+$330K	0.55%	59
2014 Q4	$453K	Buy	9,925 +325	+3%	+$15.8K	0.29%	72
2014 Q3	$542K	Hold	9,600	–	–	0.36%	71
2014 Q2	$510K	Hold	9,600	–	–	0.34%	75
2014 Q1	$502K	Hold	9,600	–	–	0.35%	71
2013 Q4	$515K	Buy	+9,600	New	+$495K	0.36%	72

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hamel Associates's SNY Position: Q4 2017 in Review

Hamel Associates sold out of Sanofi (SNY) in Q4 2017, closing a stake of 4,025 shares — an estimated $200K sold.

Hamel Associates first reported a position in SNY in Q4 2013 and held it in 14 quarters. The position peaked at $831K in Q1 2015. 504 funds tracked by Wall St. Rank hold SNY as of Q4 2017.

Hamel Associates reported no remaining Sanofi position as of Q4 2017 after selling out during the quarter.
Hamel Associates sold 4,025 Sanofi shares in Q4 2017, an estimated $200K.
Hamel Associates first reported a position in Sanofi in Q4 2013 and held it in 14 quarters.
Hamel Associates's Sanofi position peaked at $831K in Q1 2015.
504 funds tracked by Wall St. Rank held Sanofi as of Q4 2017.

Based on Hamel Associates's 13F filing for Q4 2017, filed 13 Feb 2018.